Brief Communication

Acute Myeloid Leukemia

Germline alterations in a consecutive series of acute myeloid leukemia

Published online:
  • Subscribe to Leukemia for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130:424–32.

  2. 2.

    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

  3. 3.

    Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

  4. 4.

    Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126:2484–90.

  5. 5.

    Cardoso SR, Ryan G, Walne AJ, Ellison A, Lowe R, Tummala H, et al. Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia. 2016;30:2083–6.

  6. 6.

    Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet. 2003;33:97–101.

  7. 7.

    Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–47.

  8. 8.

    Valli R, De Paoli E, Nacci L, Frattini A, Pasquali F, Maserati E. Novel recurrent chromosome anomalies in Shwachman-Diamond syndrome. Pediatr Blood Cancer. 2017;64:e26454.

  9. 9.

    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

  10. 10.

    Brown AL, Churpek JE, Malcovati L, Dohner H, Godley LA. Recognition of familial myeloid neoplasia in adults. Semin Hematol. 2017;54:60–8.

  11. 11.

    Tesi B, Davidsson J, Voss M, Rahikkala E, Holmes TD, Chiang SCC, et al. Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood. 2017;129:2266–79.

  12. 12.

    Lu C, Xie M, Wendl MC, Wang J, Mclellan MD, Leiserson MD, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015;6:10086.

  13. 13.

    Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016;122:304–11.

  14. 14.

    David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, et al. CHK1 as a therapeutic target to bypass chemoresistance in AML. Sci Signal. 2016;9:ra90.

  15. 15.

    Zare F, Dow M, Monteleone N, Hosny A, Nabavi S. An evaluation of copy number variation detection tools for cancer using whole exome sequencing data. BMC Bioinforma. 2017;18:286.

Download references


This study was funded by grants from the Academy of Finland (#274474, #312492, and #284538), the Sigrid Juselius Foundation, Helsinki University Hospital Comprehensive Cancer Research Funding, and The Finnish Funding Agency for Technology and Innovation (TEKES). We are extremely grateful to patients who participated and thus made this study possible. We thank FuGU and the FIMM Technology Center for excellent exome/Sanger sequencing services; Minna Suvela, Siv Knaappila, Annukka Ruokolainen, and Pihla Siipola for excellent technical assistance. The Aaltonen laboratory, especially Riku Katainen, is thanked for help in bioinformatics and the exome control files.

Author contributions

OK and UW-K designed the study. UW-K collected the clinical data, analyzed the results, and drafted the manuscript. EAMH analyzed the exome data, validated the mutations, and drafted the manuscript together with OK and UW-K. EP brought new ideas to the data analysis and contributed to the statistical analyses. JS, KK, and CH organized the exome sequencing at FIMM. KP organized the exome sequencing and major funding for the project. All authors have read and approved the manuscript.

Author information

Author notes

  1. These authors contributed equally: Ulla Wartiovaara-Kautto, Elina A. M. Hirvonen.


  1. Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland

    • Ulla Wartiovaara-Kautto
    •  & Kimmo Porkka
  2. Genome-Scale Biology/Research Programs Unit, and Department of Medical and Clinical Genetics/Medicum, University of Helsinki, Helsinki, Finland

    • Elina A. M. Hirvonen
    •  & Outi Kilpivaara
  3. Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

    • Esa Pitkänen
  4. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

    • Caroline Heckman
    • , Janna Saarela
    •  & Kaisa Kettunen
  5. Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland

    • Kimmo Porkka


  1. Search for Ulla Wartiovaara-Kautto in:

  2. Search for Elina A. M. Hirvonen in:

  3. Search for Esa Pitkänen in:

  4. Search for Caroline Heckman in:

  5. Search for Janna Saarela in:

  6. Search for Kaisa Kettunen in:

  7. Search for Kimmo Porkka in:

  8. Search for Outi Kilpivaara in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Outi Kilpivaara.

Electronic supplementary material